These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25385317)

  • 1. Increased Igf-I/Igfbp-3 Ratios in Postmenopausal Taiwanese with Breast Cancer, Irrespective of Er and Pr Statuses and Her2 Expression in a Case-Control Study.
    Lee SC; Tsai SM; Hou MF; Tien LY; Wu SH; Hou LA; Tsai JM; Tsai LY
    J Clin Lab Anal; 2016 Jan; 30(1):58-64. PubMed ID: 25385317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
    Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of progesterone on simultaneous, local secretion of IGFBP-3 and IGF-I [IGFBP-3/IGF-I index] by human malignant and non-malignant breast explants depends on tissue steroid receptor phenotype.
    Krzysiek J; Milewicz T; Augustowska K; Sztefko K; Ryś J; Zubel A; Pityński K; Jaszczyński P; Herman K; Basta A; Stachura J; Gregoraszczuk EŁ
    Ginekol Pol; 2003 Sep; 74(9):767-74. PubMed ID: 14674122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
    Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
    Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486).
    Milewicz T; Gregoraszczuk EL; Sztefko K; Augustowska K; Krzysiek J; Ryś J
    Growth Horm IGF Res; 2005 Apr; 15(2):140-7. PubMed ID: 15809018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBPs), and the carboxyterminal propeptide of type I procollagen (PICP) in pre- and postmenopausal women with rheumatoid arthritis.
    Szeremeta A; Jura-Półtorak A; Komosińska-Vassev K; Zoń-Giebel A; Kapołka D; Olczyk K
    Scand J Rheumatol; 2017 May; 46(3):171-179. PubMed ID: 27775453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Night work and breast cancer risk defined by human epidermal growth factor receptor-2 (HER2) and hormone receptor status: A population-based case-control study in France.
    Cordina-Duverger E; Koudou Y; Truong T; Arveux P; Kerbrat P; Menegaux F; Guénel P
    Chronobiol Int; 2016; 33(6):783-7. PubMed ID: 27078711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women.
    Grønbaek H; Flyvbjerg A; Mellemkjaer L; Tjønneland A; Christensen J; Sørensen HT; Overvad K
    Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1759-64. PubMed ID: 15533904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
    Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation of insulin-like growth factor-binding protein-1 mRNA expression following hormone replacement therapy.
    Wang HS; Wang TH; Soong YK
    Hum Reprod; 2000 Jan; 15(1):50-4. PubMed ID: 10611187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status.
    Barnes BB; Chang-Claude J; Flesch-Janys D; Kinscherf R; Schmidt M; Slanger T; Bonaterra G; Steindorf K
    Cancer Causes Control; 2009 Dec; 20(10):1985-96. PubMed ID: 19597750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
    Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y
    Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
    Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
    Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density.
    Byrne C; Colditz GA; Willett WC; Speizer FE; Pollak M; Hankinson SE
    Cancer Res; 2000 Jul; 60(14):3744-8. PubMed ID: 10919644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
    Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
    Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer.
    Pazaitou-Panayiotou K; Kelesidis T; Kelesidis I; Kaprara A; Blakeman J; Vainas I; Mpousoulegas A; Williams CJ; Mantzoros C
    Eur J Endocrinol; 2007 Feb; 156(2):187-94. PubMed ID: 17287408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?
    Wang N; Wang B; Wang Y; Hu J
    Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 in relation to breast cancer among Hispanic and white, non-Hispanic women in the US Southwest.
    Rollison DE; Giuliano AR; Risendal BC; Sweeney C; Boulware D; Laronga C; Baumgartner KB; Byers T; Slattery ML
    Breast Cancer Res Treat; 2010 Jun; 121(3):661-9. PubMed ID: 19888649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.